Phase 2 Lung Cancer Trial, Not Yet Recruiting
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People aged 18 or older, of any gender.
- People who have been diagnosed with locally advanced or metastatic non-small cell lung cancer (a type of lung cancer) that has been confirmed by laboratory testing and is not suitable for surgery or radiation therapy to cure it.
- People whose lung cancer has a specific change in a gene or protein called HER2 — this includes mutations in the HER2 gene, extra copies of the HER2 gene, or too much HER2 protein being produced.
- People who have not yet received any systemic (whole-body) treatment for their advanced lung cancer (for one treatment group in this trial).
- People who previously received a specific type of targeted therapy called a third-generation EGFR-TKI as their first treatment, and whose cancer has shown only limited or slow growth in certain areas, and who the research team believes could still benefit from continuing that treatment (for a second treatment group in this trial).
- People who previously received a specific type of targeted therapy called a third-generation EGFR-TKI as their first treatment, and whose cancer has progressed more widely, and who the research team believes are unlikely to continue benefiting from that treatment (for a third treatment group in this trial).
- People who have at least one area of cancer in the body that can be measured using standard imaging criteria at the start of the trial.
- People with a general health and activity level rated as 0 or 1 on a standard scale used by doctors — meaning fully active or able to carry out light activity (confirm with trial site).
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have cancer that has spread to the brain or the lining around the brain and is causing symptoms.
- People with a known allergy or intolerance to any ingredient in the study drugs being used in this trial.
- People who have a history of serious heart or cardiovascular disease.
- People who have a history of a lung condition called interstitial lung disease, or a similar condition caused by a drug, that required treatment with steroids, or who have had radiation-related lung inflammation.
- People who have a history of neurological (brain or nerve) conditions or mental health disorders, including epilepsy or dementia.
- People who are pregnant or currently breastfeeding.
- People who the research team considers unsuitable for the trial for any other reason.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 010-87788219
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.
Primary endpoints
Percentage of Participants With Objective Response Rate (ORR) Based on Investigator Assessment Following Treatment in Participants With HER2 alterations Non-Small-Cell Lung Cancer (NSCLC)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.